Literature DB >> 27688515

Why are statin prescribing guidelines for primary prevention not always followed in primary care?

Yasmeen Hassan1, John Ford1, Nicholas Steel1, Joanna Sheldon1, Robert Fleetcroft1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27688515      PMCID: PMC5033302          DOI: 10.3399/bjgp16X687481

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  11 in total

1.  Do the incentive payments in the new NHS contract for primary care reflect likely population health gains?

Authors:  Robert Fleetcroft; Richard Cookson
Journal:  J Health Serv Res Policy       Date:  2006-01

2.  From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia.

Authors:  K Fairhurst; G Huby
Journal:  BMJ       Date:  1998-10-24

Review 3.  Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.

Authors:  E J Mills; P Wu; G Chong; I Ghement; S Singh; E A Akl; O Eyawo; G Guyatt; O Berwanger; M Briel
Journal:  QJM       Date:  2010-10-07

4.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Authors:  Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford
Journal:  Lancet       Date:  2010-02-16       Impact factor: 79.321

5.  Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study.

Authors:  Nicola K Gale; Sheila Greenfield; Paramjit Gill; Kerry Gutridge; Tom Marshall
Journal:  BMC Fam Pract       Date:  2011-06-26       Impact factor: 2.497

6.  Statins and the risk of type 2 diabetes mellitus: cohort study using the UK clinical practice pesearch datalink.

Authors:  Ana Filipa Macedo; Ian Douglas; Liam Smeeth; Harriet Forbes; Shah Ebrahim
Journal:  BMC Cardiovasc Disord       Date:  2014-07-15       Impact factor: 2.298

7.  Using quantitative risk information in decisions about statins: a qualitative study in a community setting.

Authors:  Louisa Polak; Judith Green
Journal:  Br J Gen Pract       Date:  2015-04       Impact factor: 5.386

8.  Implications of lower risk thresholds for statin treatment in primary prevention: analysis of CPRD and simulation modelling of annual cholesterol monitoring.

Authors:  Emily McFadden; Richard Stevens; Paul Glasziou; Rafael Perera
Journal:  Prev Med       Date:  2014-11-18       Impact factor: 4.018

9.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321

10.  Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study.

Authors:  Jianhua Wu; Shihua Zhu; Guiqing Lily Yao; Mohammed A Mohammed; Tom Marshall
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more
  1 in total

1.  Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care.

Authors:  Alexander Pate; Richard Emsley; Tjeerd van Staa
Journal:  Br J Gen Pract       Date:  2020-10-29       Impact factor: 5.386

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.